Immune mechanisms in inflammatory and degenerative eye disease

Trends in Immunology

Volumn 36, Issue 6, 2015, Pages 354-363

  Perez, Victor L ^a   Caspi, Rachel R ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

Author keywords

AMD; Degeneration; Inflammation; Parainflammation; Uveitis

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYTOKINE; AUTACOID;

ADAPTIVE IMMUNITY; AGE RELATED MACULAR DEGENERATION; ANIMAL MODEL; CLINICAL FEATURE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; REVIEW; UVEITIS; ANIMAL; ANTIGEN PRESENTING CELL; IMMUNOLOGY; MACULAR DEGENERATION; T LYMPHOCYTE SUBPOPULATION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; MACULAR DEGENERATION; T-LYMPHOCYTE SUBSETS; UVEITIS;

EID: 84930822078     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.04.003     Document Type: Review

References (93)

1. Streilein J.W. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J. Leukoc. Biol. 2003, 74:179-185.
2. Forrester J.V., et al. Immune privilege or privileged immunity?. Mucosal Immunol. 2008, 1:372-381.
3. Nussenblatt R.B., et al. The immunological basis of degenerative diseases of the eye. Int. Rev. Immunol. 2013, 32:97-112.
4. Hollyfield J.G., et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 2008, 14:194-198.
5. Gu X., et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J. Biol. Chem. 2003, 278:42027-42035.
6. Anderson D., et al. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 2002, 134:411-431.
7. Cruz-Guilloty F., Perez V. Molecular medicine: defence against oxidative damage. Nature 2011, 478:42-43.
8. Cruz-Guilloty F., et al. T cells and macrophages responding to oxidative damage cooperate in pathogenesis of a mouse model of age-related macular degeneration. PLoS ONE 2014, 9:e88201.
9. Xu H., et al. Para-inflammation in the aging retina. Prog. Retin. Eye Res. 2009, 28:348-368.
10. Forrester J.V. Bowman lecture on the role of inflammation in degenerative disease of the eye. Eye (Lond.) 2013, 27:340-352.
11. Medawar P.B. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 1948, 29:58-69.
12. Caspi R.R. Ocular autoimmunity: the price of privilege?. Immunol. Rev. 2006, 213:23-35.
13. Niederkorn J.Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 2006, 7:354-359.
14. Streilein J.W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 2003, 3:879-889.
15. Zhou R., Caspi R.R. Ocular immune privilege. F1000 Biol. Rep. 2010, 2:3.
16. Niederkorn J.Y. Mechanisms of immune privilege in the eye and hair follicle. J. Investig. Dermatol. Symp. Proc. 2003, 8:168-172.
17. Streilein J.W., Stein-Streilein J. Does innate immune privilege exist?. J. Leukoc. Biol. 2000, 67:479-487.
18. Ferguson T.A., Griffith T.S. A vision of cell death: insights into immune privilege. Immunol. Rev. 1997, 156:167-184.
19. Taylor A.W. Neuroimmunomodulation and immune privilege: the role of neuropeptides in ocular immunosuppression. Neuroimmunomodulation 2002, 10:189-198.
20. Sugita S., et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br. J. Ophthalmol. 2000, 84:1130-1134.
21. Gregory M.S., et al. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J. Immunol. 2002, 169:2727-2735.
22. Ambati J., et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 2003, 9:1390-1397.
23. Cousins S., et al. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization?. Arch. Ophthalmol. 2004, 122:1013-1018.
24. Ashour H.M., Niederkorn J.Y. Gammadelta T cells promote anterior chamber-associated immune deviation and immune privilege through their production of IL-10. J. Immunol. 2006, 177:8331-8337.
25. Xu Y., Kapp J.A. gammadelta T cells are critical for the induction of anterior chamber-associated immune deviation. Immunology 2001, 104:142-148.
26. Apte R., et al. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med. 2006, 3:e310.
27. Sohn J.H., et al. Complement, innate immunity and ocular disease. Chem. Immunol. Allergy 2007, 92:105-114.
28. Jha P., et al. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol. Immunol. 2007, 44:3901-3908.
29. Sonoda K.H., et al. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 1999, 190:1215-1226.
30. Zhou R., et al. A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid. J. Immunol. 2011, 187:4170-4177.
31. Zhou R., et al. The living eye "disarms" uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition. J. Immunol. 2012, 188:1742-1750.
32. Wehrens E.J., et al. T cells out of control - impaired immune regulation in the inflamed joint. Nat. Rev. Rheumatol. 2013, 9:34-42.
33. Curnow S.J., et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest. Ophthalmol. Vis. Sci. 2005, 46:4251-4259.
34. Nussenblatt R.B., Whitcup S.M. Uveitis: Fundamentals and Clinical Practice 2010, Elsevier Health Sciences (Mosby).
35. Caspi R.R. A look at autoimmunity and inflammation in the eye. J. Clin. Invest. 2010, 120:3073-3083.
36. Nussenblatt R.B., et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am. J. Ophthalmol. 1997, 123:583-592.
37. Lee R.W., et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin. Immunopathol. 2014, 36:581-594.
38. Kastner D.L., et al. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010, 140:784-790.
39. Yamamoto J.H., et al. S-antigen specific T cell clones from a patient with Behcet's disease. Br. J. Ophthalmol. 1994, 78:927-932.
40. Chi W., et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest. Ophthalmol. Vis. Sci. 2008, 49:3058-3064.
41. Yang P., et al. Advances in pathogenesis of Behcet's disease and Vogt-Koyanagi-Harada syndrome. Ophthalmology - Current Clinical and Research Updates 2014, 443-470. Intech. P. Davey (Ed.).
42. Horai R., et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. J. Autoimmun. 2013, 44:21-33.
43. Caspi R.R. Animal models of autoimmune and immune-mediated uveitis. Drug Discov. Today: Dis. Mod. 2006, 3:3-10.
44. Luger D., et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 2008, 205:799-810.
45. Tang J., et al. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J. Immunol. 2007, 178:5578-5587.
46. Gregerson D.S., et al. Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. J. Immunol. 1999, 163:1073-1080.
47. Lambe T., et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. J. Immunol. 2007, 178:4276-4283.
48. Pennesi G., et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J. Clin. Invest. 2003, 111:1171-1180.
49. Lightman S., et al. Immunohistopathology of experimental uveitis induced by a non-ocular antigen. Curr. Eye Res. 1986, 5:857-862.
50. Thurau S.R., et al. The fate of autoreactive, GFP+ T cells in rat models of uveitis analyzed by intravital fluorescence microscopy and FACS. Int. Immunol. 2004, 16:1573-1582.
51. Anderson M.S., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
52. Chen J., et al. Comparative analysis of induced vs. spontaneous models of autoimmune uveitis targeting the interphotoreceptor retinoid binding protein. PLoS ONE 2013, 8:e72161.
53. Prendergast R.A., et al. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest. Ophthalmol. Vis. Sci. 1998, 39:754-762.
54. The Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
55. Javitt J.C., et al. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003, 110:1534-1539.
56. Bressler S., et al. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch. Ophthalmol. 1990, 108:1442-1447.
57. Holz F., et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2001, 42:1051-1056.
58. Beatty S., et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 2000, 45:115-134.
59. Edwards A., et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:412-424.
60. Gold B., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006, 38:458-462.
61. Hageman G., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7227-7232.
62. Klein R., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385-389.
63. Yates J., et al. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 2007, 357:553-561.
64. Nussenblatt R.B., et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010, 30:1579-1587.
65. Umeda S., et al. Early-onset macular degeneration with drusen in a cynomolgus monkey (Macaca fascicularis) pedigree: exclusion of 13 candidate genes and loci. Invest. Ophthalmol. Vis. Sci. 2005, 46:683-691.
66. Engel H.M., et al. Degenerative changes in maculas of rhesus monkeys. Ophthalmologica 1988, 196:143-150.
67. Dawson W.W., et al. Maculas, monkeys, models, AMD and aging. Vision Res. 2008, 48:360-365.
68. Haines J.L., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
69. Coffey P., et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16651-16660.
70. Combadière C., et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 2007, 117:2920-2928.
71. Tuo J., et al. Genetics of immunological and inflammatory components in age-related macular degeneration. Ocul. Immunol. Inflamm. 2012, 20:27-36.
72. Mattapallil M.J., et al. The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes. Invest. Ophthalmol. Vis. Sci. 2012, 53:2921-2927.
73. Tobe T., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 1998, 153:1641-1646.
74. Youssef P., et al. Retinal light toxicity. Eye (Lond.) 2011, 25:1-14.
75. Espinosa-Heidmann D., et al. Cigarette smoke-related oxidants and the development of sub-RPE deposits in an experimental animal model of dry AMD. Invest. Ophthalmol. Vis. Sci. 2006, 47:729-737.
76. Fujihara M., et al. Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS ONE 2008, 3:e3119.
77. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
78. Liu B., et al. Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J. Transl. Med. 2011, 15:1-12.
79. Morohoshi K., et al. Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration. J. Autoimmun. 2009, 33:247-254.
80. Morohoshi K., et al. Identification of anti-retinal antibodies in patients with age-related macular degeneration. Exp. Mol. Pathol. 2012, 93:193-199.
81. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun. Rev. 2003, 2:63-68.
82. Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun. Rev. 2009, 8:410-414.
83. Morohoshi K., et al. Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization. Exp. Mol. Pathol. 2012, 92:64-73.
84. Weismann D., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
85. Zhao H., et al. Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2013, 54:5321-5331.
86. Kaplan H.J., et al. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 1999, 5:292-297.
87. Takase H., et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int. Immunol. 2005, 17:1131-1140.
88. Narfstrom K., et al. Reduced level of interphotoreceptor retinoid-binding protein (IRBP), a possible cause for retinal degeneration in the Abyssinian cat. Cell Tissue Res. 1989, 257:631-639.
89. Sych F.J., Strobel J. Experiences with an isolation method for retinal S-antigen and interphotoreceptor retinoid-binding protein. Ophthalmologe 1996, 93:732-738.
90. Agarwal R.K., et al. Rodent models of experimental autoimmune uveitis. Methods Mol. Biol. 2012, 900:443-469.
91. Ufret-Vincenty R.L., et al. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest. Ophthalmol. Vis. Sci. 2010, 51:5878-5887.
92. Tuo J., et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J. 2004, 18:1297-1299.
93. Tuo J., et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2007, 48:3827-3836.